Japan has approved zongertinib as a first-line treatment for patients with unresectable, advanced or recurrent HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC), expanding access to an oral targeted therapy earlier in the treatment pathway.
Announced by Boehringer Ingelheim on November 16, 2026, the decision extends the drug’s September 2025 Japanese approval for previously treated disease. It follows first-line approvals in the United States and China. The Japanese announcement specifies that the expanded indication was granted under the country’s conditional approval system.
Zongertinib Moves Into First-Line Treatment
Zongertinib is an oral, irreversible tyrosine kinase inhibitor designed to selectively inhibit HER2 while sparing wild-type EGFR, an approach intended to limit toxicities associated with EGFR inhibition.
HER2 mutations occur in up to 4% of NSCLC cases. For this molecularly defined group, effective targeted treatment options have historically been limited, particularly before patients receive other systemic therapies. The expanded approval makes zongertinib available as an initial treatment option in Japan.
Beamion LUNG-1 Results Supporting the Approval
The decision was based on the primary analysis of a previously untreated cohort in Beamion LUNG-1, an international Phase Ia/Ib clinical trial.
Among 74 patients, the objective response rate was 70.3% (95% CI, 57.8–80.3). Complete responses occurred in 2.7% and partial responses in 67.6%, while the disease control rate reached 94.6%.
These results formed the efficacy dataset cited in the Japanese approval announcement.
Updated Results Show a 76% Response Rate
Updated findings published in The New England Journal of Medicine provide further information on response durability and progression-free survival.
In the 74-patient first-line cohort, participants received zongertinib at 120 mg once daily. At the August 21, 2025 data cutoff, the confirmed objective response rate was 76% (95% CI, 65–84). Median duration of response was 15.2 months, and median progression-free survival was 14.4 months.
The 76% response rate comes from the updated publication; the Japanese approval announcement cites the earlier primary-analysis rate of 70.3%. These figures should therefore be presented as separate analyses.
The trial also evaluated a separate exploratory cohort of 30 patients with active brain metastases. In this group, 47% achieved a confirmed intracranial objective response, providing evidence of activity within the central nervous system. This finding was separate from the first-line cohort results.
Safety Findings in Previously Untreated Patients
In the approval dataset, drug-related adverse events occurred in 90.5% of patients, including Grade 3 or higher events in 18.9%. Diarrhea was the most frequently reported adverse event, affecting 55.4%; Grade 3 or higher diarrhea occurred in 2.7%.
The updated publication reported Grade 3 or higher adverse events from any cause in 45% of patients, compared with treatment-related events of that severity in 19%. This distinction is important when interpreting the overall safety findings.
What Comes Next for First-Line Zongertinib?
Beamion LUNG-1 provides evidence of response and durability, but its first-line cohort does not establish superiority over another treatment.
The Phase III Beamion LUNG-2 trial is evaluating zongertinib against standard treatment in previously untreated patients with unresectable, locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain mutations. The randomized study will provide comparative evidence to help define zongertinib’s role in first-line care.
Read more on OncoDaily: Boehringer Ingelheim Expands Its Cancer Innovation Pipeline With SBP Group
